Perspective Therapeutics (CATX) Change in Receivables (2010 - 2026)
Perspective Therapeutics (CATX) posted Change in Receivables of $52000.0 for Q1 2026, up 130.06% sequentially from -$173000.0 in Q4 2025, and up 236.84% YoY from $15437.5 in Q1 2025.
Perspective Therapeutics (CATX) Change in Receivables (2010 - 2026) Analysis & Trends
Perspective Therapeutics has reported Change in Receivables for 17 years, with the latest figure at $52000.0 in Q1 2026.
- Quarterly Change in Receivables rose 236.84% year-over-year to $52000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20000.0 (up 97.83% YoY) and the FY2025 annual result came in at -$110000.0, up 89.51% from the prior year.
- Change in Receivables improved to $52000.0 in Q1 2026 per CATX's latest filing, from -$173000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $618000.0 in Q3 2023 and troughed at -$813000.0 in Q2 2024.
- A 5-year average of -$90000.0 and a median of -$46000.0 in 2025 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2023 and 2024: Change in Receivables surged 242.4% in 2023, then sank 16700.0% in 2024.
- Over 5 years, Change in Receivables stood at -$245000.0 in 2022, then tumbled by 131.02% to -$566000.0 in 2023, then surged by 61.66% to -$217000.0 in 2024, then advanced by 20.28% to -$173000.0 in 2025, then soared by 130.06% to $52000.0 in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $52000.0, -$173000.0, and -$46000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 386.00 Mn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 177.00 Mn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 287.00 Mn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 46.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 10.20 Mn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 172.10 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 79.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | - |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -90.00 Mn |
| 10 | Perspective Therapeutics | 389.10 Mn | 389.10 Mn | - | 211,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 211,000.00 |
| Jun 30, 2026 | 211,000.00 |
| Mar 31, 2026 | 52,000.00 |
| Mar 31, 2026 | 52,000.00 |
| Dec 31, 2025 | -173,000.00 |
| Dec 31, 2025 | -173,000.00 |
| Sep 30, 2025 | -46,000.00 |
| Sep 30, 2025 | -46,000.00 |
| Jun 30, 2025 | 147,000.00 |
| Jun 30, 2025 | 147,000.00 |
| Mar 31, 2025 | -38,000.00 |
| Mar 31, 2025 | -38,000.00 |
| Dec 31, 2024 | -217,000.00 |
| Dec 31, 2024 | -217,000.00 |
| Sep 30, 2024 | 147,000.00 |
| Sep 30, 2024 | 147,000.00 |
| Jun 30, 2024 | -813,000.00 |
| Jun 30, 2024 | -813,000.00 |
| Mar 31, 2024 | -166,000.00 |
| Mar 31, 2024 | -166,000.00 |